News stories about Alexion Pharmaceuticals (NASDAQ:ALXN) have been trending somewhat positive on Sunday, Accern reports. Accern scores the sentiment of media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Alexion Pharmaceuticals earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave news articles about the biopharmaceutical company an impact score of 45.4206588014024 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near future.

Here are some of the media stories that may have impacted Accern Sentiment Analysis’s analysis:

Alexion Pharmaceuticals (NASDAQ ALXN) traded up $2.81 during trading hours on Friday, reaching $117.92. The company had a trading volume of 1,343,726 shares, compared to its average volume of 2,169,027. The stock has a market capitalization of $26,140.62, a price-to-earnings ratio of 60.16, a PEG ratio of 1.09 and a beta of 1.13. Alexion Pharmaceuticals has a 52-week low of $96.18 and a 52-week high of $149.34. The company has a debt-to-equity ratio of 0.34, a quick ratio of 2.62 and a current ratio of 3.10.

Alexion Pharmaceuticals (NASDAQ:ALXN) last released its earnings results on Thursday, February 8th. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.09 by $0.39. The firm had revenue of $909.70 million during the quarter, compared to analyst estimates of $880.38 million. Alexion Pharmaceuticals had a return on equity of 12.94% and a net margin of 12.48%. Alexion Pharmaceuticals’s revenue was up 9.5% compared to the same quarter last year. During the same period last year, the business posted $1.26 earnings per share. equities analysts anticipate that Alexion Pharmaceuticals will post 6.12 earnings per share for the current fiscal year.

Several research analysts recently weighed in on the company. ValuEngine lowered Alexion Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Thursday. Deutsche Bank set a $161.00 price objective on Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, February 9th. BMO Capital Markets increased their price objective on Alexion Pharmaceuticals from $177.00 to $180.00 and gave the stock an “outperform” rating in a research report on Friday, February 9th. Citigroup lowered their price objective on Alexion Pharmaceuticals from $173.00 to $170.00 and set a “buy” rating for the company in a research report on Friday, February 9th. Finally, Stifel Nicolaus reiterated a “buy” rating and issued a $151.00 price objective on shares of Alexion Pharmaceuticals in a research report on Friday, February 9th. Three analysts have rated the stock with a sell rating, one has assigned a hold rating and twenty have given a buy rating to the company. The company has a consensus rating of “Buy” and a consensus target price of $152.77.

In related news, SVP Heidi L. Wagner sold 698 shares of Alexion Pharmaceuticals stock in a transaction on Wednesday, February 28th. The stock was sold at an average price of $119.35, for a total value of $83,306.30. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Ludwig Hantson sold 2,553 shares of Alexion Pharmaceuticals stock in a transaction on Tuesday, January 2nd. The shares were sold at an average price of $121.63, for a total value of $310,521.39. Following the completion of the transaction, the chief executive officer now owns 36,172 shares of the company’s stock, valued at $4,399,600.36. The disclosure for this sale can be found here. Over the last quarter, insiders sold 31,253 shares of company stock valued at $3,656,229. 4.35% of the stock is currently owned by company insiders.

TRADEMARK VIOLATION WARNING: This piece was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at

Alexion Pharmaceuticals Company Profile

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Insider Buying and Selling by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with's FREE daily email newsletter.